Skip to main content

Additional Articles by the Author

Radiation May Be Safely Omitted in Favorable-Risk Breast Cancer Patients Aged 50 to 69 Years

Conference Highlights ASCO, Lung Cancer

Atezolizumab Extends Disease-Free Survival in PD-L1−Positive Early-Stage NSCLC

Phoebe Starr

Prostate Cancer, Conference Highlights ASCO

¹⁷⁷Lu-PSMA-617 Prolongs Survival in Patients with Metastatic Castration-Resistant Prostate Cancer

Phoebe Starr

Renal-Cell Carcinoma, Conference Highlights ASCO

Adjuvant Pembrolizumab Therapy Significantly Extends Disease-Free Survival in Patients with Clear-Cell Renal-Cell Carcinoma

Phoebe Starr

Prostate Cancer

¹⁷⁷Lu-PSMA-617 Superior to Cabazitaxel in Metastatic Prostate Cancer

Phoebe Starr

Momelotinib, a Novel JAK Inhibitor, Makes Inroads in Intermediate- or High-Risk Myelofibrosis

Phoebe Starr

First-Line Fixed-Duration Ibrutinib plus Venetoclax Therapy Leads to Deep Remissions in Patients with Chronic Lymphocytic Leukemia

Phoebe Starr

Emerging Therapies

Novel Target: RARA Agonist plus Azacitidine Active in Relapsed or Refractory Acute Myeloid Leukemia

Phoebe Starr

Asciminib, First-in-Class STAMP Inhibitor, Superior to Bosutinib in Chronic-Phase CML

Phoebe Starr

Graft-versus-Host Disease

Ruxolitinib in Graft-versus-Host Disease: Practice-Changing Results

Phoebe Starr

1
2
3
4

Page 1 of 9
Results 1 - 10 of 89